OBJECTIVE: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. DESIGN: Randomized, single-blind, placebo-controlled trial. SETTING: General clinical research center. PATIENTS: Thirteen healthy, nonobese premenopausal women. INTERVENTION(S): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. MAIN OUTCOME MEASURE(S): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. RESULT(S): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 10.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. CONCLUSION(S): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
RCT Entities:
OBJECTIVE: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. DESIGN: Randomized, single-blind, placebo-controlled trial. SETTING: General clinical research center. PATIENTS: Thirteen healthy, nonobese premenopausal women. INTERVENTION(S): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. MAIN OUTCOME MEASURE(S): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. RESULT(S): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 10.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. CONCLUSION(S): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
Authors: R J Walker; N J Lewis-Barned; W H Sutherland; A Goulding; E A Edwards; S A de Jong; E Gold; H L Walker Journal: Menopause Date: 2001 Jan-Feb Impact factor: 2.953
Authors: G Perseghin; P Scifo; E Pagliato; A Battezzati; S Benedini; L Soldini; G Testolin; A Del Maschio; L Luzi Journal: J Clin Endocrinol Metab Date: 2001-07 Impact factor: 5.958
Authors: Peter R Casson; Michael J Toth; Julia V Johnson; Frank Z Stanczyk; Colleen L Casey; Marjorie E Dixon Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958
Authors: Shrita M Patel; Nayyar Iqbal; Shailja Kaul; Sarah J Ratcliffe; Michael R Rickels; Muredach P Reilly; Theresa Scattergood; Arpita Basu; Carissa Fuller; Anne R Cappola Journal: Fertil Steril Date: 2010-03-12 Impact factor: 7.329
Authors: C Lawrence Kien; Janice Y Bunn; Naomi K Fukagawa; Vikas Anathy; Dwight E Matthews; Karen I Crain; David B Ebenstein; Emily K Tarleton; Richard E Pratley; Matthew E Poynter Journal: J Nutr Biochem Date: 2015-08-01 Impact factor: 6.048
Authors: Michael J Toth; Brian C Cooper; Richard E Pratley; Andrea Mari; Dwight E Matthews; Peter R Casson Journal: Am J Physiol Endocrinol Metab Date: 2008-04-15 Impact factor: 4.310